Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia - Wikidata - wikimedia - TriplyDB

Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia

Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia

http://www.wikidata.org/entity/Q35409569

about

The emerging roles of exosomes in leukemogeneis Mechanisms of Nuclear Export in Cancer and Resistance to Chemotherapy A hostel for the hostile: the bone marrow niche in hematologic neoplasms Nuclear transport of galectin-3 and its therapeutic implications Galectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via β-catenin/GSK-3β modulation in colorectal carcinoma Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms Dysregulation of galectin-3. Implications for Hermansky-Pudlak syndrome pulmonary fibrosis.Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway.The involvement of Galectins in the modulation of the JAK/STAT pathway in myeloproliferative neoplasia Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.Low or No Inhibitory Potency of the Canonical Galectin Carbohydrate-binding Site by Pectins and Galactomannans Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang.Propagation of trimethylated H3K27 regulated by polycomb protein EED is required for embryogenesis, hematopoietic maintenance, and tumor suppression.Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.The hematopoietic stem cell niche--home for friend and foe?Extracellular galectin-3 in tumor progression and metastasis.Galectin-3 inhibitors: a patent review (2008-present).Galectins as therapeutic targets for hematological malignancies: a hopeful sweetness.Myeloid malignancies and the microenvironment.FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells.Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway.Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors.Expression profiling of cancer-related galectins in acute myeloid leukemia.Galectin-3 in pre-B acute lymphoblastic leukemia.Molecular pathways: involving microenvironment damage responses in cancer therapy resistance.Role of Galectins in Multiple Myeloma.Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia.Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.Molecular mechanism to recruit galectin-3 into multivesicular bodies for polarized exosomal secretion.[Chronic myeloid leukemia stem cells: cross-talk with the niche].Clinical significance of galectin-3 in patients with adult acute myeloid leukemia: a retrospective cohort study with long-term follow-up and formulation of risk scoring system.Multiple Roles of Glycans in Hematological Malignancies Extracellular galectins as controllers of cytokines in hematological cancer

P2860

Q26748606-3F702129-92AA-4327-A7AC-67602263D203 Q26764837-57D0D2DB-7C0C-40B7-B5EC-41BFF384EBE6 Q26777629-D92F58AC-6537-4415-8D08-013CD3556D29 Q26824889-F6EF21F7-CA69-422E-8E95-470EB02AB207 Q28535429-42D3B085-0F4B-4E38-BB23-C936F7E69EFD Q30361951-14C96EEA-FD68-45CA-89BE-AAF0211DBB27 Q31077729-8D44427A-E761-44C5-BDE8-7DAF723CB9D8 Q33799623-520E93FC-E080-439E-9199-E4C718CF1A31 Q35096615-E97731AC-A4E1-4550-95D5-AAD612D5063A Q36062042-E68343AE-DB91-4208-A9A6-9CFBA5FB3D2C Q36642752-E373B4A7-6747-4ED7-87EA-F6A2275ABD7C Q37065931-94C0ADB6-F7E3-4690-92CC-822B6818F614 Q37094051-9EDA281B-F2DD-4317-B5F2-6110CC5E5A14 Q37264244-34DABD65-625C-4E98-93B7-8D23B8DCDF31 Q38057413-2A006CC1-F7D9-4451-B675-F1E7B2CE3BB5 Q38071041-770A3518-03C8-42A9-B7B6-90E394D1BD37 Q38225141-0CFFC787-4BDD-480D-B932-D12E379D3222 Q38238525-BD858D38-EB9F-47AF-A333-24F5304FC13B Q38269046-89B0C8C6-F045-4AF6-A306-CA7ABFDD701F Q39073878-89552F0B-DA81-41BC-9C51-78CA3DA0F970 Q39126141-EA2E8A11-C192-4465-A30D-B2C91F02E144 Q39475895-DE65A781-F24A-4710-B242-68FC6E40EBA2 Q41370892-AD15213D-C833-4008-8DBC-B2256BDBD956 Q41575103-3895FB3A-9E3B-45B1-9DFB-C7FB0DA0521A Q41753912-8E603577-A310-4B66-93A3-E297C0DC3903 Q41891815-FAAFF2AB-7F52-4755-AC31-02910502FF8A Q42006859-AA6BF4F3-5979-4693-A9CC-50B5C52B2E95 Q47282400-88C02B7F-D565-4ECE-A913-A81283B8BAC7 Q47783708-7EB28C9C-1CA3-49FA-A2B6-F3A7861994F8 Q51122167-DB4F008B-231D-42E4-AE70-8463E2C1CFC3 Q52312098-6CE3A814-BD68-4D93-9263-230F6463E10A Q54354799-A53F391C-194C-437E-B795-409471C863C7 Q54697325-FD09C2D1-F6DE-4259-9B3E-D288F35FF390 Q58761454-240F2DAF-5749-499C-9682-A04CD54A5982 Q58803547-B5CB98D5-321B-4136-9918-A2B9EAD34E59

P2860

Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia

http://www.wikidata.org/entity/Q35409569

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Galectin-3 (Gal-3) induced by ...... n chronic myelogenous leukemia

@ast

Galectin-3 (Gal-3) induced by ...... n chronic myelogenous leukemia

@en

type

label

Galectin-3 (Gal-3) induced by ...... n chronic myelogenous leukemia

@ast

Galectin-3 (Gal-3) induced by ...... n chronic myelogenous leukemia

@en

prefLabel

Galectin-3 (Gal-3) induced by ...... n chronic myelogenous leukemia

@ast

Galectin-3 (Gal-3) induced by ...... n chronic myelogenous leukemia

@en

P1433

Q35409569-58AFDCB7-59A1-4F9D-A85E-46390D9AB03F

P1476

Q35409569-B4BA0B01-29BA-48EA-B02D-CCD7139A8CC7

P2093

Q35409569-6EB44C97-1110-4FF6-8BAB-5315B9B9D57E

Q35409569-7641CF29-569E-4D68-92B3-92A2BBF99E83

Q35409569-7A2D9CC3-BF2E-45BB-A702-FB3754879515

Q35409569-8B890B05-4EA9-4F1E-B30E-B61AC620C75F

Q35409569-8D4B14AE-4456-40EB-A117-44239C8A01DE

Q35409569-962B12BA-1A8B-4AFB-8037-116C5E03E60A

Q35409569-AF5AEF82-3C00-4E90-BF65-BDB8B0811953

Q35409569-B0F194BC-E84E-4188-BDE6-1825FEC4434F

Q35409569-C29DF23B-5D5C-4F39-9B2D-90ED41177146

Q35409569-D6D6DEBC-F936-481E-804A-950CDFCAA3F0

P2860

Q35409569-0631B95E-222C-461B-AC27-E773AA6B665F

Q35409569-12054CF3-06FB-4B0E-9661-1231010A1E8D

Q35409569-180704D9-71F7-445F-8D73-9308F7F5AAC6

Q35409569-1BBFA7A9-A2E5-4B6E-94A7-88B050F445D1

Q35409569-1E84F58A-D484-4A27-A11F-62F4BBFF48CF

Q35409569-20674485-9B73-431F-BA19-D811D231235E

Q35409569-2869B73E-1957-485E-A78D-6D8F1ED65DDC

Q35409569-296D6555-2AAA-4686-9ADC-303E39782334

Q35409569-2A922A9E-97AB-4FEA-AD35-DC11BE838875

Q35409569-2B0B4AC6-25CD-49CB-B231-8C54793F4834

P304

Q35409569-8CEC19A6-8248-447A-AFB6-38191D621D43

P31

Q35409569-F9820C47-382E-44E5-B554-407A94732904

P356

Q35409569-1116DCA8-0C31-42B2-B06A-DC18F80B9C83

P407

Q35409569-97150947-53CA-4F26-8179-8213A4296F23

P433

Q35409569-581F7EB8-E1FF-4B41-BBDF-F329D5E9832E

P478

Q35409569-F1E9E717-21F5-4521-A146-FE050E188287

P577

Q35409569-552B17DB-5BCC-4AA8-B7F2-D795D87721A1

P5875

Q35409569-6002F40F-E02C-424A-B695-48E17F939A89

P698

Q35409569-68522CC0-688D-4803-AA1D-4B555415FC7B

P921

Q35409569-36506B3C-67C9-48AE-8202-EE800A0DC7F0

P932

Q35409569-9702CC34-53F7-4C06-9BF1-06EF74E0429B

P356

PNAS.1111138108

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Galectin-3 (Gal-3) induced by ...... n chronic myelogenous leukemia

@en

P2093

Eishi Ashihara

http://www.w3.org/2001/XMLSchema#string

Hisao Nagoshi

http://www.w3.org/2001/XMLSchema#string

Junya Kuroda

http://www.w3.org/2001/XMLSchema#string

Kenichi Akaji

http://www.w3.org/2001/XMLSchema#string

Masafumi Taniwaki

http://www.w3.org/2001/XMLSchema#string

Miki Kiyota

http://www.w3.org/2001/XMLSchema#string

Mio Yamamoto-Sugitani

http://www.w3.org/2001/XMLSchema#string

Nana Sasaki

http://www.w3.org/2001/XMLSchema#string

Nobuhiko Uoshima

http://www.w3.org/2001/XMLSchema#string

Ryuko Nakayama

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of galectin-3 modulates T-cell growth and apoptosis

p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Emerging drugs for chronic myeloid leukemia.

Chronic myeloid leukemia: mechanisms of blastic transformation

Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.

Models of chronic myeloid leukemia.

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model.

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

P304

17468-17473

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1111138108

http://www.w3.org/2001/XMLSchema#string

P407

P433

42

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51708206

http://www.w3.org/2001/XMLSchema#string

P698

21987825

http://www.w3.org/2001/XMLSchema#string

P921

P932

3198366

http://www.w3.org/2001/XMLSchema#string